Recent 8-K filings for SVRA
Highest-materiality recent filing
Savara reports positive Phase 3 IMPALA-2 results for molgramostim in aPAP; primary endpoint met
- Primary endpoint met: DLCO improved by 6.00% predicted at Week 24 vs placebo (p=0.0007).
- Statistically significant improvement sustained at Week 48: DLCO 6.90% (p=0.0008).
-
Savara amends Hercules loan; adds $75M drawdown tied to FDA approval of MOLBREEVI
Amends $105M loan agreement; new $45M and $30M tranches available upon FDA approval of MOLBREEVI for aPAP.
-
Savara prices $130M public offering of common stock and pre-funded warrants at $4.20/share
23.8M shares at $4.20/share and 7.1M pre-funded warrants at $4.199/warrant for gross proceeds of $130M.
-
Savara secures $75M royalty funding from RTW for MOLBREEVI; also discloses securities class action
RTW commits $75M upon FDA approval of MOLBREEVI for autoimmune PAP; funds to support U.S. launch and repay debt.
-
Savara receives FDA Refusal to File for MOLBREEVI BLA; resubmission expected Q4 2025
FDA requested additional CMC data; RTF not due to safety or efficacy concerns.
-
Savara secures up to $200M non-dilutive debt from Hercules Capital, $30M drawn at close
$30M initial draw used to repay existing $26.5M SVB debt; up to $170M additional available contingent on FDA approval of MOLBREEVI and other milestones.
-
Savara prices $100M common stock offering at $3.81/sh, 26.2M shares
Gross proceeds of ~$100M from 26,246,720 shares at $3.81 per share.
-
Savara reports positive Phase 3 IMPALA-2 results for molgramostim in aPAP; primary endpoint met
Primary endpoint met: DLCO improved by 6.00% predicted at Week 24 vs placebo (p=0.0007).
Materiality & sentiment trend
Max materiality 0.90 · Median 0.40 · Most common event other_material